A61K 31/4745
Condensed with ring systems having nitrogen as a ring hetero atom
Official title: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
A61K31/4745 (Condensed with ring systems having nitrogen as a ring hetero atom) appears on 2,782 US grants and 5,660 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,782
- Published applications
- 5,660
- Assignees
- 1,902
- Inventors
- 9,626
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 3 | 0 |
| 1996 | 6 | 0 |
| 1997 | 20 | 0 |
| 1998 | 17 | 0 |
| 1999 | 24 | 0 |
| 2000 | 21 | 0 |
| 2001 | 22 | 8 |
| 2002 | 31 | 111 |
| 2003 | 63 | 157 |
| 2004 | 53 | 185 |
| 2005 | 41 | 213 |
| 2006 | 47 | 262 |
| 2007 | 55 | 242 |
| 2008 | 48 | 121 |
| 2009 | 45 | 121 |
| 2010 | 70 | 176 |
| 2011 | 102 | 162 |
| 2012 | 72 | 141 |
| 2013 | 94 | 174 |
| 2014 | 127 | 236 |
| 2015 | 142 | 273 |
| 2016 | 152 | 327 |
| 2017 | 160 | 303 |
| 2018 | 206 | 269 |
| 2019 | 186 | 308 |
| 2020 | 189 | 289 |
| 2021 | 181 | 297 |
| 2022 | 160 | 271 |
| 2023 | 122 | 277 |
| 2024 | 112 | 291 |
| 2025 | 134 | 246 |
| 2026 | 76 | 200 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method of treating SCLC and managing neutropenia29 Sep 2026US 12,746,240 B2Pharma Mar, S. A.
- Nitrogen-containing heterocyclic compound having MYT1 inhibitory activity29 Sep 2026US 12,747,239 B2Chugai Seiyaku Kabushiki Kaisha
- Camptothecin derivatives29 Sep 2026US 12,747,250 B2ImmunoGen, Inc.
- TLR7/8 antagonists and uses thereof22 Sep 2026US 12,740,978 B2Merck Patent GmbH
- Anti-CLDN18.2 antibody, drug conjugate, and preparation method therefor and use thereof22 Sep 2026US 12,741,032 B2Cspc Megalith Biopharmaceutical Co., Ltd.
- Modified liposome for drug delivery, use of liposome for drug delivery, especially with anti-cancer activity, and ways to load liposome with drugs, especially with anti-cancer activity8 Oct 2026US 2026/0306403 A1Bs Biotechna Spolka Akcyjna
- Nanoparticles for photoimmune therapy comprising photosensitizer and adjuvant, and usage thereof8 Oct 2026US 2026/0306632 A1Korea Institute of Science and Technology
- Deuterated camptothecin compound, and preparation therefor and use thereof8 Oct 2026US 2026/0308167 A1Shanghai Qilu Pharmaceutical Research and Development Centre Ltd.
- Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan1 Oct 2026US 2026/0294894 A1Ipsen Biopharm Ltd.
- Combination therapy comprising a mat2a inhibitor and a topoisomerase inhibitor, a splicing inhibitor sulfonamide, or a kif18 inhibitor1 Oct 2026US 2026/0294915 A1Glaxosmithkline Intellectual Property (No. 4) Ltd.
Most cited
By later US patents
- Controlled local delivery of chemotherapeutic agents for treating solid tumors349US 5,626,862 AMassachusetts Institute of Technology · 1997
- Immune response modifier compounds for treatment of TH2 mediated and related diseases285US 6,039,969 A3M Innovative Properties Company · 2000
- Formulations and methods for treatment of mucosal associated conditions with an immune response modifier272US 6,245,776 B13M Innovative Properties Company · 2001
- Imidazonaphthyridines255US 6,194,425 B13M Innovative Properties Company · 2001
- Sulfonamide and sulfamide substituted imidazoquinolines255US 6,331,539 B13M Innovative Properties Company · 2001